About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

NICE Reconsiders Fingolimod for MS

by Kathy Jones on March 18, 2012 at 12:28 AM
Font : A-A+

 NICE Reconsiders Fingolimod for MS

British drug regulator National Institute for Health and Clinical Excellence (NICE) has overturned its initial rejection of drug fingolimod due to cost concerns and said that it can be used to treat people with highly active relapsing multiple sclerosis.

The drug, sold under the brand name Gilenya by Novartis, has an annual cost of Ģ20,000 per patient and analysts believe that it could help thousands of patients with relapsing MS with recent studies showing that it can reduce the number of relapses by as much as 60 percent.

Advertisement

Stating that the drug was a cost effective option for NHS, Professor Carole Longson, Director of the Health Technology Evaluation Centre at NICE said, "Following new information provided during the consultation, the analyses show that for these people, treatment with fingolimod will be a cost effective option for the NHS in this group of people with multiple sclerosis, if Novartis provides the drug at a discounted price, as proposed in its patient access scheme."




Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Loram (2 mg) (Lorazepam) Drug Side Effects Calculator Daily Calorie Requirements Selfie Addiction Calculator The Essence of Yoga Iron Intake Calculator Diaphragmatic Hernia Blood Donation - Recipients Blood Pressure Calculator Blood - Sugar Chart
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use